Combination treatment for metastatic pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism, Lungs & breathing clinical trials.
This trial tests a new combination of treatments for people with advanced pancreatic cancer that has spread to the liver or lungs. It includes a cancer vaccine, two chemotherapy drugs, an immunotherapy drug, and a heat-based therapy to see if it can help shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced or recurrent pancreatic cancer that has spread to the liver or lungs.
- Your tumor has a specific genetic change called KRAS G12V (this is found by a special test).
- You have already tried a type of chemotherapy called AG-based (like gemcitabine) and it didn't work or you couldn't tolerate it.
- You are generally able to take care of yourself (ECOG score of 0 or 1), and your liver and kidney function are good enough.
- You have not had previous local treatments like radiofrequency ablation, microwave ablation, or radiation for the cancer that spread to your liver or lungs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new tumor vaccine combined with a standard chemotherapy regimen (AG) for people with metastatic pancreatic cancer. It aims to see if the combination is safe and helps the immune system fight the cancer.
This study tests a new treatment combining tumor destruction with heat/cold (ablation) and an immunotherapy drug (PD-1) for people whose pancreatic cancer has spread to the liver. The goal is to help the immune system fight the cancer better.
This trial tests a new targeted drug (HRS-4642) combined with nimotuzumab and chemotherapy for people with advanced pancreatic cancer that has a specific gene change called KRAS G12D. It's for those who haven't had treatment for advanced disease yet.
This trial tests whether combining two experimental drugs (GFH375 with GFS202A or GFH276) works better than one drug alone for people with advanced pancreatic cancer that has a specific genetic change called KRAS G12D. It may offer a new option for those who have already tried other treatments.
This trial tests a combination of three drugs—capecitabine (a chemotherapy pill), camrelizumab (an immunotherapy), and apatinib (a targeted therapy)—for people with advanced pancreatic cancer whose previous treatment stopped working or who cannot tolerate standard chemotherapy.
This trial tests whether adding bortezomib and an immunotherapy drug to standard chemotherapy can help people with pancreatic cancer that has spread to other organs. It is for patients who have not had treatment or whose cancer has worsened after gemcitabine-based chemotherapy.
Hear when a new Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.